{
    "paper_id": "PMC7194856",
    "metadata": {
        "title": "Chloroquine and COVID-19, where do we stand?\u2606",
        "authors": [
            {
                "first": "M.",
                "middle": [],
                "last": "Lecuit",
                "suffix": "",
                "email": "marc.lecuit@pasteur.fr",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "It has been known for a while that chloroquine (C) and its derivative hydroxychloroquine (HC) inhibit in vitro the replication of viruses which envelope fuses with that of the acidified endosome. These drugs indeed prevent endosome acidification and virologists and cell biologists are well aware of this. The in vitro antiviral activity of C and HC against SARS-CoV-2 reported a few weeks ago was therefore expected [1], [2]. C and HC may have other mechanisms of action to block SARS-CoV-2 replication, which will need to be deciphered.",
            "cite_spans": [
                {
                    "start": 417,
                    "end": 420,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 422,
                    "end": 425,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "However, in vitro results do not necessarily translate in vivo. Indeed, numerous clinical trials with disappointing results have been reported with C, including on dengue (no benefit) and chikungunya (deleterious effect). Therefore, concluding before testing it in humans that this treatment will be effective in COVID-19 is premature. This is well explained in the recently published article by the virologist X. de Lamballerie [3].",
            "cite_spans": [
                {
                    "start": 429,
                    "end": 432,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "A two-page article published a few weeks ago indicated\u2013without presenting results\u2013that clinical trials performed in China have shown the effectiveness of this treatment in COVID-19 [4]. If these clinical trials have been adequately performed and their results are convincing, they are either in press or will be published very soon in a top-tier scientific journal, just like the recent article evaluating lopinavir and ritonavir published in the New England Journal of Medicine. This latter clinical trial failed to prove the effectiveness of this treatment [5].",
            "cite_spans": [
                {
                    "start": 181,
                    "end": 184,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 559,
                    "end": 562,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "In the following video (https://www.youtube.com/watch?v=8L6ehRif-v8), Didier Raoult mentions that clinical trials conducted in China evaluating C/HC in COVID-19 were successful, although their results are yet to be published. Didier Raoult suggested prescribing this treatment on a large scale, and decided to perform a study aimed at demonstrating that HC is effective in vivo against SARS-CoV-2. The results of this study have just been published [6]. The Supplementary Figure 1 from Raoult's publication illustrates that they are preliminary. The viral load of asymptomatic patients or patients presenting with mild disease was the only parameter evaluated, and some of these patients seemed to be at the end of the infectious process [7]. The publication conditions of this article also raised issues [8].",
            "cite_spans": [
                {
                    "start": 449,
                    "end": 452,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 738,
                    "end": 741,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 805,
                    "end": 808,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "This does not by any mean imply that HC is not beneficial in patients with COVID-19. But to assess its potential benefits, HC has to be scientifically evaluated in compliance with the methodology of clinical trials. This is currently ongoing as clinical trials are being performed, but this requires a bit of time because of the necessary methodological constraints, even in an emergency setting. If HC/C antiviral effectiveness against SARS-CoV-2 is proven in human\u2013which we all wish for\u2013its positioning will have to be defined: as a preventive treatment, to treat all cases and case contacts at the end of a containment period to prevent a new wave of transmission? As a preventive treatment for severe infection in at-risk patients (population to be defined)? As a curative treatment of severe presentations? Perhaps not only as the sudden worsening of patients with COVID-19 (ARDS) is probably not only due to uncontrolled viral replication, but also to intense inflammation leading to alveolar tissue destruction. This is why drugs such as anti-IL6 are currently being tested, and may end-up being proven beneficial at this late stage of the disease.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Another issue lies in the currently limited availability of these drugs, although pharmaceutical laboratories have started their mass production in anticipation of a potentially large use. Advising everyone via YouTube, Twitter, and mainstream media to take this potentially miracle cure seems dangerous because it could lead to shortage, with a potential negative impact on patients who would benefit the most from this treatment. Moreover, although successfully used by Didier Raoult's team and others for many years for other purposes, these molecules are not without toxicity, especially when used on a large scale. C/HC is known for inducing QT interval prolongation and may thus lead to cardiac arrests. It could thus be dangerous to use it without careful clinical supervision. Besides, azithromycin \u2212suggested to act in combination with C/HC against SArs-CoV-2 [6]\u2212 is also known for inducing QT interval prolongation. Suggesting a mass combination therapy without prior evaluation of its potential toxicity when used on a large scale seems potentially dangerous.",
            "cite_spans": [
                {
                    "start": 869,
                    "end": 872,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "This does not prevent many clinicians, in France and throughout the world, from using HC in the management of COVID-19 while waiting for clinical trials results, considering the seriousness of the situation and the current absence of proven efficacy of any antiviral therapy for COVID-19. This approach differs from communicating information that seems definitive to the general public, when it is actually only preliminary.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Il est connu depuis bien longtemps que la chloroquine (C) et son d\u00e9riv\u00e9 l\u2019hydroxychloroquine (HC) inhibent in vitro la r\u00e9plication des virus envelopp\u00e9s dont le relargage du g\u00e9nome dans le cytosol par fusion de la membrane virale avec celle de l\u2019endosome requiert une acidification. En effet, ces drogues bloquent l\u2019acidification du pH endosomal. Ces donn\u00e9es sont bien connues des virologues et biologistes cellulaires. Il a \u00e9t\u00e9 montr\u00e9 il y a quelques semaines que, comme attendu, la C et l\u2019HC ont une activit\u00e9 antivirale sur le SARS CoV 2 in vitro [1], [2].",
            "cite_spans": [
                {
                    "start": 548,
                    "end": 551,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 553,
                    "end": 556,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Il est possible que la C et l\u2019HC agissent \u00e9galement par d\u2019autres m\u00e9canismes, et cela doit \u00eatre \u00e9tudi\u00e9. Cela n\u2019implique pas n\u00e9cessairement cependant que ces drogues ont une activit\u00e9 antivirale in vivo chez l\u2019\u00eatre humain. Il y a eu en effet moult essais d\u00e9cevants, concernant le virus de la dengue (pas de b\u00e9n\u00e9fice) ou du chikungunya (effet d\u00e9l\u00e9t\u00e8re), donc conclure que ce traitement va \u00eatre efficace avant de l\u2019avoir test\u00e9 est probl\u00e9matique. L\u2019article du virologue X. de Lamballerie explique bien cela [3].",
            "cite_spans": [
                {
                    "start": 501,
                    "end": 504,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Il y a quelques semaines un article de deux pages a \u00e9t\u00e9 publi\u00e9, qui dit sans montrer aucun r\u00e9sultat que des essais cliniques conduits en Chine ont montr\u00e9 une efficacit\u00e9 [4].",
            "cite_spans": [
                {
                    "start": 169,
                    "end": 172,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Si ces essais ont \u00e9t\u00e9 bien conduits et les r\u00e9sultats probants, ils ont toutes chances d\u2019\u00eatre sous presse dans une grande revue (ou sont en voie de l\u2019\u00eatre), comme cela vient d\u2019\u00eatre le cas pour l\u2019article sur lopinavir et ritonavir dans le New England Journal of Medicine . Cet essai n\u2019a pas montr\u00e9 d\u2019efficacit\u00e9 [5].",
            "cite_spans": [
                {
                    "start": 309,
                    "end": 312,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Dans la vid\u00e9o suivante (https://www.youtube.com/watch?v=8L6ehRif-v8) Didier Raoult fait r\u00e9f\u00e9rence \u00e0 ces essais sur C/HC conduits en Chine, dont les r\u00e9sultats ne sont toujours pas \u00e0 ce jour disponibles, et propose que ce traitement soit utilis\u00e9 \u00e0 large \u00e9chelle. Il a \u00e9galement d\u00e9cid\u00e9 de d\u00e9montrer que l\u2019HC a une efficacit\u00e9 in vivo contre le SARS-CoV-2 en conduisant une \u00e9tude, dont les r\u00e9sultats viennent d\u2019\u00eatre publi\u00e9s [6].",
            "cite_spans": [
                {
                    "start": 419,
                    "end": 422,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "La Suppl. Fig. 1 illustre que ces r\u00e9sultats sont pr\u00e9liminaires. Seule la charge virale chez des patients asymptomatiques ou peu graves a \u00e9t\u00e9 \u00e9valu\u00e9e. Il semble que certains de ces malades \u00e9taient en fin d\u2019infection [7].",
            "cite_spans": [
                {
                    "start": 215,
                    "end": 218,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "D\u2019autre part les conditions de la publication de cet article ont soulev\u00e9 des questions [8].",
            "cite_spans": [
                {
                    "start": 87,
                    "end": 90,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Ces interrogations n'impliquent pas que l\u2019HC n\u2019a pas d\u2019int\u00e9r\u00eat dans le traitement du COVID.Il faut \u00e9valuer scientifiquement son efficacit\u00e9 \u00e9ventuelle en suivant la m\u00e9thodologie des essais cliniques. Ceci est en cours dans des essais qui prennent un peu de temps car travailler avec m\u00e9thode le n\u00e9cessite, m\u00eame dans l\u2019urgence. Au cas o\u00f9 une r\u00e9elle efficacit\u00e9 antivirale sur le SARS-CoV-2 est prouv\u00e9e chez l'\u00eatre humain, ce que tous souhaitent, il faudra pr\u00e9ciser les indications d\u2019un tel traitement: En pr\u00e9vention, pour traiter tous les cas et leurs contacts en sortie de confinement et emp\u00eacher la reprise de la transmission? En pr\u00e9vention d\u2019une infection grave chez les personnes \u00e0 risque d\u2019en d\u00e9velopper (d\u00e9finir cette population). En traitement de la maladie grave? Peut-\u00eatre pas uniquement car \u00e0 ce stade, l\u2019aggravation brutale qui survient (ARDS) n\u2019est sans doute pas uniquement la r\u00e9sultante d\u2019une r\u00e9plication virale incontr\u00f4l\u00e9e mais d\u2019une r\u00e9action inflammatoire qui s\u2019emballe. C\u2019est la raison pour laquelle sont aujourd\u2019hui test\u00e9es des drogues telles que des anti IL1 et IL6, qui pourraient avoir un int\u00e9r\u00eat.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Enfin ces drogues sont en quantit\u00e9s limit\u00e9es pour l\u2019instant m\u00eame si les laboratoires pharmaceutiques ont lanc\u00e9 en pr\u00e9vision d\u2019un usage potentiel large une production massive. Dire \u00e0 tous par You tube et Twitter interpos\u00e9s et dans la presse grand public qu\u2019il faut absolument prendre ce traitement miracle semble dangereux car cela risque engendrer une p\u00e9nurie qui pourrait avoir un impact sur les patients qui en auraient le plus besoin. D\u2019autre part ces mol\u00e9cules, quand bien m\u00eame elles sont utilis\u00e9es avec succ\u00e8s dans l\u2019\u00e9quipe de Didier Raoult et au-del\u00e0 depuis de nombreuses ann\u00e9es, ne sont pas d\u00e9nu\u00e9es de toxicit\u00e9, surtout si elles sont utilis\u00e9es \u00e0 grande \u00e9chelle. La C/HC allonge l'intervalle QT, et peut donc engendrer des arr\u00eats cardiaques, et ainsi provoquer plus de morts que sauver de vies s\u2019il est utilis\u00e9 sans discernement. De plus l\u2019azithromycine, qui est propos\u00e9e en association et pourrait avoir un int\u00e9r\u00eat \u00e9galement, augmente \u00e9galement le QT. Il appara\u00eet donc potentiellement dangereux de proposer ce traitement de masse sans en avoir \u00e9valu\u00e9 les cons\u00e9quences \u00e9ventuelles.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Ceci n\u2019emp\u00eache pas de nombreux coll\u00e8gues cliniciens, en France et dans le monde, d\u2019utiliser l\u2019HC dans la prise en charge du COVID, dans l\u2019attente des r\u00e9sultats des essais cliniques, compte tenu de la gravit\u00e9 de la situation. Cette approche est diff\u00e9rente de la communication au grand public d\u2019informations qui semblent d\u00e9finitives alors qu\u2019elles ne le sont pas.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "The author declares that he has no competing interest.",
            "cite_spans": [],
            "section": "Disclosure of interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "269-271",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Discov",
            "volume": "6",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Of chloroquine and COVID- 19",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Touret",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "de Lamballerie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Antiviral research",
            "volume": "177",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Jianjun Gao",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhenxue Tian",
                    "suffix": ""
                },
                {
                    "first": "Yang.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BioScience Trends",
            "volume": "14",
            "issn": "",
            "pages": "72-73",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Bin Cao",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Yeming Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Danning Wen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wen Liu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jingli Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Guohui Fan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2001282"
                ]
            }
        },
        "BIBREF5": {
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrobial Agents",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF6": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}